|
|
|
| The present situation and prospect of Buyang Huanwu Decoction combined with interventional therapy for diabetic foot |
| LIU Wenbin1 WANG Jianbo2 GUI Dingkun3 |
1.Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2.Department of Radiology Intervention, Eastern Hospital of Shanghai Sixth People′s Hospital Affiliated to Shanghai University of Medicine ＆ Health Sciences, Shanghai 201306, China;
3.Department of Nephrology, Eastern Hospital of Shanghai Sixth People′s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 201306, China |
|
|
|
Abstract Diabetic foot is a common complication of diabetes and the main cause of amputation in diabetic patients. Traditional Chinese medicine, as a traditional medical means in China, has a good effect on the treatment of diabetic foot ulcer, foot vascular stenosis and diabetic peripheral neuropathy, and intervention, as a new emerging technology in recent years, has a good effect on the treatment of diabetic peripheral blood vessel stenosis and occlusion. In recent years, many hospitals have achieved good results in the innovative application of traditional Chinese medicine prescriptions of invigorating qi and strengthening the body, invigorating blood circulation and resolving blood stasis combined with interventional therapy for diabetic feet. Buyang Huanwu Decoction has been widely used in the clinical application of diabetic foot as a classical prescription for invigorating qi and activating blood circulation to clear collaterals. This paper introduces the current situation of Buyang Huanwu Decoction combined with interventional therapy for diabetic foot and its treatment prospect from four aspects: the establishment of collateral circulation, the change of peripheral nerves, the speed of wound healing and the improvement of blood glucose and lipid.
|
|
|
|
|
|
[1] Qinan W，Bing C，Ziwen L. Mesenchymal Stem Cells as a Prospective Therapy for the Diabetic Foot [J]. Stem Cells International，2016，2016：4612167.
[2] Sun NF，Tian AL，Tian YL，et al. The interventional therapy for diabetic peripheral artery disease [J]. BMC Surg，2013，13（1）：1-6.
[3] 张朝光，戴黎明，杨夏.糖尿病足患者下肢血管病变与细菌感染的关系研究[J].中华医院感染学杂志，2018，28（1）：51-54，61.
[4] Kota SK，Kota SK，Meher LK，et al. Surgical revascularization techniques for diabetic foot [J]. J Cardiovasc Dis Res，2013，4（2）：79-83.
[5] Xiaoping Z，Weishuai L，Wensheng L，et al. Transcatheter Arterial Infusion of Autologous CD133+ Cells for Diabetic Peripheral Artery Disease [J]. Stem Cells Int，2016，2016：6925357.
[6] Fowkes FGR，Rudan D，Rudan I，et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010：a systematic review and analysis [J]. lancet，2013，382（9901）：1329-1340.
[7] 张瑞鹏，戴维.经皮腔内血管成形术联合血管内支架植入术治疗下肢动脉硬化闭塞症的疗效观察[J].临床医学研究与实践，2017，2（18）：62-63.
[8] 张磊，穆永旭，闫瑞强，等.丹参红花汤剂浸泡双足联合介入治疗老年糖尿病足效果观察[J].中国继续医学教育，2016，8（6）：186-187.
[9] 刘文泉，公茂亮，颜冰，等.补阳还五汤配合介入法治疗糖尿病足的临床研究[J].中国中医骨伤科杂志，2016，24（11）：35-37.
[10] Meloni M，Izzo V，Del Giudice，et al. Recurrence of Critical Limb Ischemia After Endovascular Intervention in Patients with Diabetic Foot Ulcers [J]. Adv Wound Care，2018，7（6）：171-176.
[11] Zhu X，Guo J，He C，et al. Ultrasound triggered image-guided drug delivery to inhibit vascular reconstruction via paclitaxel-loaded microbubbles [J]. Scientific Reports，2016，6：21683.
[12] Li H，Jiang Z，Liu X，et al. Higher plasma level of STIM1，OPG are correlated with stent restenosis after PCI [J]. Int Clin Exp Med，2015；8（11）：21089-21097.
[13] Wang H，Robichaux WG，Wang Z，et al. Inhibition of Epac1 suppresses mitochondrial fission and reduces neointima formation induced by vascular injury [J]. Sci Rep，2016， 6：36552.
[14] Yin K，Agrawal DK. High-density lipoprotein：a novel target for antirestenosis therapy [J]. Clin Transl Sci，2014，7（6），500-511.
[15] 王日生，蔡俊，张继平.补阳还五汤对大鼠急性脑缺血再灌注损伤的保护作用及机制[J].实用医学杂志，2015， 31（5）：725-727.
[16] 李振华.补阳还五汤对脑缺血再灌注模型大鼠血小板聚集及血栓形成的影响[J].中医学报，2018，33（3）：422-425.
[17] 刘国才.补阳还五汤应用于糖尿病足介入治疗后的疗效观察[J].糖尿病新世界，2016，19（7）：52-53.
[18] 李强，于宗学，苗进.益气活血法预防糖尿病足腔内介入后再狭窄的观察[J].中医临床研究，2014，6（36）：61-63.
[19] Dietrich I，Braga GA，de Melo FG；da Costa Silva Silva ACC. The Diabetic Foot as a Proxy for Cardiovascular Events and Mortality Review[J]. Curr Atheroscler Rep，2017，19（11）：44-49.
[20] 钟建林.补阳还五汤配合中药泡足治疗糖尿病周围神经病变疗效观察[J].糖尿病新世界，2017，20（6）：164-165
[21] 贲莹，张凤华，梁文杰，等.不同黄芪剂量补阳还五汤对糖尿病大鼠周围神经功能及氧化应激的作用[J].中成药，2015，37（1）：199-202.
[22] 国际血管联盟中国分会糖尿病足专业委员会.糖尿病足诊治指南[J].介人放射学杂志，2013，22（9）：705-708.
[23] Zhao B，Zhang X，Han W，et al. Wound healing effect of an Astragalus membranaceus polysaccharide and its mechanism [J]. Mol Med Rep，2017，15（6）：4077-4083.
[24] 王灵犀.补阳还五汤联合化腐生肌膏外敷治疗糖尿病足临床观察[J].四川中医，2015，33（11）：63-64.
[25] 董芳，张德生.补阳还五汤联合复荣通脉胶囊治疗糖尿病周围血管病变临床研究[J].陕西中医，2017，38（12）：1714-1716.
[26] Tam Jc，Ko CH，Lau KM，et al. A Chinese 2-herb formula（NF3）promotes hindlimb ischemia-induced neovascularization and wound healing of diabetic rats [J]. J Diabes Complications，2014，28（4）：436-47.
[27] 史衍杰，盖艳，段大航.红花黄色素注射液治疗糖尿病并发症的研究进展[J].中国医院用药评价与分析，2015， 15（11）：1556-1557.
[28] 何伟，柳国斌，张定棋，等.基于数据挖掘的糖尿病足中药熏洗处方用药规律研究[J].云南中医学院学报，2017， 40（3）：87-90.
[29] Brenneman J，Hill J，Pullen S. Emerging therapeutics for the treatment of diabetic nephropathy [J]. Bioorg Med Chem Lett，2016，26（18）：4394-4402.
[30] Eissa S，Matboli M，Bekhet MM. Clinical verification of a novel urinary microRNA panal：133b，-342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis [J]. Biomed Pharmacother，2016，83：92-99.
[31] 李土明，吴滢，徐丽英，等.补阳还五汤对APOE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响[J].新中医，2018，50（2）：5-8.
[32] 陆晋.补阳还五汤对2型糖尿病患者血糖、血脂水平的影响及临床疗效观察[J].当代医学，2017，23（34）：83-84.
[33] 马翔，闫霖.补阳还五汤治疗气虚血瘀型单纯性高血压临床疗效观察[J].辽宁中医药大学学报，2018，20（3）：98-100.
[34] 陈奎铭，王小平，蔡惠群.中医中药治疗糖尿病足溃疡的临床研究近况[J].现代中西医结合杂志，2017，26（4）：454-456. |
|
|
|
